Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 8S-21S

  Hirsh, J ^a   Dalen, J E ^a   Anderson, D R ^a   Poller, L ^a   Bussey, H ^a   Ansell, J ^a   Deykin, D ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMINOGLUTETHIMIDE; AMIODARONE; ANABOLIC AGENT; ANTICOAGULANT AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CIGARETTE SMOKE; CIMETIDINE; CLOFIBRATE; COLESTYRAMINE; COTRIMOXAZOLE; COUMARIN ANTICOAGULANT; DICLOXACILLIN; ERYTHROMYCIN; FLUCONAZOLE; GRISEOFULVIN; ISONIAZID; LATAMOXEF; METRONIDAZOLE; MICONAZOLE; NAFCILLIN; OMEPRAZOLE; PENICILLIN G; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; RIFAMPICIN; SULFINPYRAZONE; UNINDEXED DRUG; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ALCOHOL INTERACTION; DRUG DISPOSITION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; ISCHEMIA; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TOBACCO; TREATMENT INDICATION; VALVULAR HEART DISEASE;

EID: 0035128503     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.8S     Document Type: Conference Paper

References (165)

1. Mechanisms of coumarin action: Significance of vitamin K epoxide reductase inhibition
2. Evidence that warfarin anticoagulant action involves two distinct reductase activities
3. The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin
4. Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3 epoxide: Evidence for multiple pathways of hydroxyvitamin K formation
5. Vitamin K dependent modifications of glutamic acid residues in prothrombin
6. The mode of action of vitamin K: Identification of γ-carboxyglutamic acid as a component of prothrombin
7. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin treated patients
8. The kinetics of activation of normal and gamma carboxy glutamic acid deficient prothrombins
9. Role of γ-carboxyglutamic acid: An unusual transition required for calcium-dependent binding of prothrombin to phospholipid
10. Differentiation of metal ion-induced transitions of prothrombin fragment 1
11. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid
12. Osteocalcin and matrix Gla protein: Vitamin K dependent proteins in bone
13. Role of vitamin K-dependent proteins in bone metabolism
14. Protein S, a vitamin K-dependent protein is a bone matrix component synthesized and secreted by osteoblasts
15. Sequence of the precursor to rat bone γ-carboxyglutamic acid protein that accumulated in warfarin-treated osteosarcoma cells
16. Congenital malformations associated with the administration of oral anticoagulants during pregnancy
17. Maternal and fetal sequelae of anticoagulation during pregnancy
18. Long-term use of oral anticoagulants and the risk of fracture
19. Oral anticoagulant drugs: Pharmacokinetic aspects
20. Vitamin K and other oral anticoagulant drugs
21. Clinical pharmacokinetics of oral anticoagulants
22. Warfarin metabolism and drug-drug interactions
23. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
24. Genetic control of anticoagulation
25. Determinants of the response to oral anticoagulant drug in man
26. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man
27. Studies on the optical enantiomorphs of warfarin in man
28. 12C labeled racemates of warfarin in man
29. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy
30. The warfarin-sulfinpyrazone interaction: Stereochemical considerations
31. The stereoselective interaction of warfarin and metronidazole in man
32. Stereoselective interaction of trimethoprimsulfamethoxazole with the separated enantiomorphs of racemic warfarin in man
33. Warfarin: Stereochemical aspects of its metabolism and the interaction with phenylbutazone
34. Interaction of amiodorone with racemic warfarin and its separated enantiomorphs in humans
35. A review of enzyme induction of warfarin metabolism with recommendations for patient management
36. Hereditary resistance to coumarin anticoagulant drugs in man and rat
37. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs
38. Hereditary warfarin resistance
39. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism
40. Missence mutations at ALA-10 in the Factor IX propeptide: An insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy
41. Recognition site directing vitamin K-dependent γ-carboxylation resides on the propeptide of factor IX
42. Resistance to warfarin due to unrecognized vitamin K supplementation
43. Vitamin K deficiency from dietary vitamin K restriction in humans
44. Structure and mechanism of activation of vitamin K antagonists
45. Mechanisms of vitamin K metabolism and vitamin K-dependent hemostasis: Implications for warfarin therapy
46. 1 content
47. Influence of fever upon the action of 3,3-methylene bis-(4- hydroxoycoumarin)
48. Effect of sodium dextrothyroxine in patients receiving anticoagulants
49. 1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins
50. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration
51. Studies on the interaction of warfarin and clofibrate in man
52. Acetaminophen and other risk factors for excessive warfarin anticoagulation
53. Acetaminophen and warfarin: Undesirable synergy
54. Hematological pertubations associated with salicylate
55. Bleeding during acetysalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement
56. Interaction of ibuprofen and warfarin on primary hemostasis
57. Effects of penicillin G on platelet aggregation, release and adherence to collagen
58. The hemostatic defect produced by carbenicillin
59. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein
60. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole
61. Aspirin and warfarin after heart-valve replacement: A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement
62. Assessment of short-term anticoagulant administration after cardiac infarction: Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis
63. Effect of erythromycin in patients receiving long-term warfarin therapy
64. Potentiation of warfarin anticoagulation by topical testosterone treatment
65. Human sources and absorption of vitamin K in relation to anticoagulation
66. The interaction of warfarin with drugs and food: A critical review of the literature
67. Drug interactions with oral anticoagulants
68. Drug interactions with coumarin anticoagulants
69. Acetaminophen and risk factors for excess anticoagulation with warfarin
70. Acetaminophen and risk factors for excess anticoagulation with warfarin
71. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin
72. Warfarin: From bedside to bench
73. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin-K dependent clotting factors
74. Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma
75. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
76. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring anticoagulant therapy
77. Comparison of 5-mg and 1O-mg loading doses in initiation of warfarin therapy
78. The prothrombin time in hemophilia and in obstructive jaundice
79. Standardization of laboratory tests for controlling anticoagulant therapy
80. Progress in standardization in anticoagulant control
81. An evaluation of chromogenic substrates in the control of oral anticoagulant therapy
82. Dosage and control of oral anticoagulants: An international survey
83. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio
84. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy
85. Results of a multicentre study assessing the status of a recombinant thromboplastin
86. Is the dose of warfarin prescribed by American physicians unnecessarily high?
87. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy
88. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: Comparison with the prothrombin time ratio
89. Assessment of the validity of the INR system for patients with liver impairment
90. Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalized ratios (INR)
91. Laboratory monitoring of anticoagulants
92. Discrepant results in INR testing
93. Proficiency testing and standardization of prothrombin time: Effect of thromboplastin, instrumentation, and plasma
94. The value of plasma calibrants in correcting coagulometer effects on international normalized ratios: An international multicenter study
95. The effect of some instruments for prothrombin time testing on the international sensitivity index (ISI) of two rabbit tissue thromboplastin reagents
96. Comparison of two automated coagulometers and the manual tilt tube method for determination of prothrombin time
97. Effect of automation on the prothrombin time test in NEQAS surveys
98. The dependence of the international sensitivity index on the coagulometer used to perform the prothrombin time
99. Correction of instrument and reagent based differences in determination of the international normalized ratio (INR) for monitoring anticoagulant therapy
100. Automation and prothrombin time: A United Kingdom field study of two widely used coagulometers
101. The correction of coagulometer effects on international normalized ratio: A multicentre evaluation
102. A comparison of lyophilized artificially depleted plasma and lyophilized plasma from warfarin treated in correcting for coagulometer effects on international normalized ratios
103. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of oral anticoagulant therapy
104. Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time: A report of the subcommittee for control of anticoagulation
105. Failure of the international normalized ratio to generate consistent results within a local medical community
106. Laboratory control of oral anticoagulants
107. Evaluation of international normalized ratios by a controlled field survey with 4 different thromboplastin reagents
108. The correction of coagulometer effects on international normalised ratios: A multicentre evaluation
109. A comparison of artificially depleted, lyophilized coumarin and fresh coumarin plasmas in thromboplastin calibration: European Concerted Action on Anticoagulation (ECAA)
110. Field studies of coagulometer effects on the ISI of ECAA thromboplastins: The European Concerted Action on Anticoagulation (ECAA)
111. Monitoring warfarin therapy in patients with lupus anticoagulants
112. Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants
113. Thrombosis in the antiphospholipid antibody syndrome
114. The international normalized ratio (INR) for monitoring warfarin therapy: Reliability and relation to other monitoring methods
115. Plasma levels of factors II, VII, and X and their relationship to the international normalized ratio during chronic warfarin therapy
116. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis
117. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention in ischemic heart disease in men at increased risk
118. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
119. Prevention of venous thrombosis and pulmonary embolism in injured patients
120. Two-step warfarin therapy: Prevention of postoperative venous thrombosis without excessive bleeding
121. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip
122. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis
123. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery
124. Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial
125. Reduction of factor VII coagulant activity (VIIC), a risk factor for ischemic heart disease, by fixed dose warfarin: A double blind crossover study
126. Prevention of venous thrombosis with minidose warfarin after joint replacement
127. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement
128. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery, despite inhibiting the postoperative rise in plasminogen activator inhibitor activity
129. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
130. The optimal duration of anticoagulant therapy for venous thrombosis
131. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis
132. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
133. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
134. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
135. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
136. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
137. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group
138. Deep venous thrombosis and lupus anticoagulant: A case-control study
139. Anticardiolipin antibodies and recurrent thromboembolism
140. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene
141. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
142. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction: Coumadin Aspirin Reinfarction Study
143. Adjusted dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
144. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
145. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
146. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: A prospective clinical trial
147. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement
148. Trial of different intensities of anticoagulation in patients with prosthetic heart valves
149. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves
150. The optimal intensity of oral anticoagulant therapy in patients with mechanical heart valve prostheses: The Leiden artificial valve and anticoagulation study
151. Guidelines for prevention of thromboembolic events in valvular heart disease: Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology
152. The stroke prevention in atrial fibrillation study: Final results
153. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
154. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study
155. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
156. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
157. Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trials
158. Anticoagulation and atrial fibrillation
159. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
160. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study
161. Antithrombotic therapy for cerebrovascular disorders: An update